(lp0
S'Keep An Eye On Rexahn Pharmaceuticals Inc  This Year Insider Financial - Mar 13, 2017 Rexahn Pharmaceuticals, Inc.  ran up towards the end of last week on basically no news, and is running again early session in the US on Monday.The Epic Rise of Rexahn Pharmaceuticals, Inc.  - The Oracle DispatchWhy Analysts put forward these two stocks: Rexahn Pharmaceuticals, Inc. (RNN ... - The USA Commerce'
p1
aS'Rexahn Pharmaceuticals  Jumps: Stock Moves Up 5.4% March 16, 2017 Zacks.com - Mar 16, 2017 Rexahn Pharmaceuticals, Inc.  was a big mover last session, as its shares rose above 5% on the day.'
p2
aS"Rexahn Pharmaceuticals, Inc.  Announces Full Year 2016 Financial Results Smarter Analyst - Feb 27, 2017 Rexahn Pharmaceuticals, Inc.  announced financial results for the year ended December 31, 2016 and provided an update on the Company's clinical development programs.Shares of Rexahn Pharmaceuticals, Inc.  Plunge -4.8% - Energy IndexWhich insiders are trading Rexahn Pharmaceuticals, Inc. ? - Post Analyst"
p3
aS'Rexahn Pharmaceuticals, Inc.  From A Bullish Perspective Smarter Analyst - Oct 11, 2016 When a tumor-targeted therapy company advances in clinical trials, pay attention. Rexahn Pharmaceuticals  should be closely watched.'
p4
aS'Stock Update : Rexahn Pharmaceuticals, Inc. Provides Update on ... Smarter Analyst - Jan 20, 2017 Rexahn Pharmaceuticals, Inc.  announced an update on the safety and efficacy of RX-3117 in an ongoing Phase IIa clinical trial in metastatic pancreatic cancer at the American Society for Clinical Oncology  2017 Gastrointestinal&nbsp;...'
p5
aS'Rexahn Pharmaceuticals, Inc.  Initiates Clinical Trial to Evaluate the ... Smarter Analyst - Feb 23, 2017 Rexahn Pharmaceuticals, Inc.  announced that is has begun enrolling patients into a Phase IIa clinical study of Supinoxin in metastatic triple negative breast cancer .'
p6
aS"What are Analyst's Indicators for Catabasis Pharmaceuticals, Inc. (CATB ... The USA Commerce - Mar 13, 2017 Shares of Catabasis Pharmaceuticals, Inc.  surged 53.38% to $2.04. During the trading on 03/10/2017, Company's stock ranged from $1.58 to $2.76. The relative strength index or RSI highlights overbought  and oversold (below&nbsp;...Biotech Stocks Worth a Closer Look: Catabasis Pharmaceuticals, Inc. (NASDAQ ... - The Voice RegistrarBiotech Stocks Worth Chasing: Catabasis Pharmaceuticals, Inc. , Rexahn ... - The Independent Republic"
p7
aS'Stock Under Radar: Rexahn Pharmaceuticals, Inc.  The Oracle Examiner - 14 hours ago Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Rexahn Pharmaceuticals, Inc.  is showing beta of -0.16. This particular value of beta suggests that Rexahn Pharmaceuticals, Inc.  has ...Stock Price Rexahn Pharmaceuticals, Inc.  Compared to Index - Highland MirrorStocks to Keep Your Eyes on: RPC Inc. , Rexahn Pharmaceuticals, Inc ... - TopChronicle'
p8
aS"Is It Time to go for Rexahn Pharmaceuticals, Inc. , TG Therapeutics, Inc ... StockNewsJournal - Mar 10, 2017 ROI deals with the invested cash in the company and the return the investor realize on that money based on the net profit of the business.Rexahn Pharmaceuticals, Inc. : A Detailed Look at its Institutional Ownership - Post AnalystRexahn Pharmaceuticals, Inc.'s  stock price is Worth at $0.32 while ... - Hot Stocks Point"
p9
aS"Most Active Stock Update: Rexahn Pharmaceuticals, Inc.  HugoPress - Mar 15, 2017 MLV &amp; Co. Initiates Coverage on Rexahn Pharmaceuticals, Inc. 's stock to Buy with the price target of $1.3."
p10
a.